CompletedNo phase
Ultra-low Dose Contrast for Endovascular Procedures
Key facts
- Who runs it
- Attikon Hospital
- Where
- Greece1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 18 people enrolled
- Started
- 1 Sept 2024
- Ended
- 23 Jan 2026
- Type of study
- Observational
- Treatments tested
- Infrainguinal peripheral endovascular revascularization
- Record updated
- 10 March 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- CLTI
- Prescheduled infrainguinal revascularization procedure
- Renal disease stage 2-4 (eGFR <60ml/minute/1.73m2)
- Adequate pre- and post-procedural hydration protocol
Who cannot take part
- End-stage renal disease/ dialysis
- Endovascular treatment of Iliac artery steno-oclussive disease
- Allergy to contrast media
- eGFR >60ml/minute/1.73m2)
- Inadequate pre- and post-procedural hydration protocol
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this protocol is to study the safety and feasibility of using ultra-low dose iodinated contrast agent for infrainguinal endovascular revascularization procedures in patients with chronic limb-threatening lower limb ischemia (CLTI) and impaired renal function, in the new angiography suite of our department.
The group in the trial
- Study cohort
Patients with renal disease stages 2-4, scheduled to undergo infrainguinal endovascular procedures due to CLTI, using ultra-low dose of iodine contrast media.
Treatment: Infrainguinal peripheral endovascular revascularization
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Feasibility Study of the Use of Ultra-low Dose Iodinated Contrast Agent for Endovascular Procedures in Patients With Chronic Limb-threatening Ischemia and Renal Impairment
- Record updated
- 10 March 2026